HARMONi-3
SMT112-3003

Phase III

Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients

2022-502168-19-00

CA239-0004
Krystal-4

Phase III

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab
Plus Chemotherapy in Participants With Previously Untreated Non-squamous
Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

2024-515698-85

M24-536

Phase I/II

An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal
Dose of Telisotuzumab Adizutecan in Combination With Budigalimab in Advanced or
Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and
No Actionable Genomic Alterations

2024-514465-18  

MK1084
KANDLELIT-014

Phase II

A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as

Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant,

Advanced Solid Tumors (KANDLELIT-014)

EU-CT-Nummer:  2025-521737-91

M25-713

AndroMETa-Lung-713

Phase II/III

A Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects with Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713

EU-CT-Nummer: 2025-521124-29